induced pluripotent stem cell (iPSC) reprogramming
GPTKB entity
Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biological pathway
|
| gptkbp:alsoKnownAs |
iPSC reprogramming
|
| gptkbp:alternativeTo |
embryonic stem cell derivation
|
| gptkbp:associatedWith |
histone modification
epigenetic changes DNA methylation changes |
| gptkbp:canBe |
gptkb:keratinocytes
fibroblasts viral vectors blood cells somatic cells episomal vectors mRNA transfection non-viral methods protein delivery |
| gptkbp:enables |
regenerative medicine
disease modeling drug screening generation of patient-specific stem cells |
| gptkbp:firstDemonstrated |
gptkb:Shinya_Yamanaka
2006 |
| https://www.w3.org/2000/01/rdf-schema#label |
induced pluripotent stem cell (iPSC) reprogramming
|
| gptkbp:involves |
cellular dedifferentiation
introduction of reprogramming factors |
| gptkbp:NobelPrizeYear |
2012 Nobel Prize in Physiology or Medicine
|
| gptkbp:produces |
induced pluripotent stem cells
|
| gptkbp:riskFactor |
genomic instability
tumorigenicity |
| gptkbp:studiedIn |
regenerative medicine research
cellular reprogramming research disease modeling research |
| gptkbp:uses |
gptkb:Klf4
gptkb:Sox2 gptkb:c-Myc gptkb:Oct4 |
| gptkbp:bfsParent |
gptkb:POU5F1
|
| gptkbp:bfsLayer |
7
|